VIDEO: Faricimab shows encouraging results for diabetic macular edema treatment

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The recent FDA approval of faricimab, the first bispecific intravitreal agent that blocks both VEGF and angiopoietin-2 is an exciting development. The clinical trials demonstrated that faricimab is noninferior to 2 mg of aflibercept, and more importantly, it suggests that faricimab could be dosed less frequently, with many patients being dosed every 12 weeks or every 16 weeks. I think this presents a great treatment option for our patients allowing for disease control with fewer treatments over time. I am encouraged by these results, and I think many retina specialists are employing faricimab in their clinical practice to allow patients to get better disease control with excellent visual acuity outcomes.